291 related articles for article (PubMed ID: 19527507)
1. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience.
Gupta T; Agarwal JP; Ghosh-Laskar S; Parikh PM; D'Cruz AK; Dinshaw KA
Head Neck Oncol; 2009 Jun; 1():17. PubMed ID: 19527507
[TBL] [Abstract][Full Text] [Related]
2. Conventional radiotherapy with concurrent weekly Cisplatin in locally advanced head and neck cancers of squamous cell origin - a single institution experience.
Dimri K; Pandey AK; Trehan R; Rai B; Kumar A
Asian Pac J Cancer Prev; 2013; 14(11):6883-8. PubMed ID: 24377620
[TBL] [Abstract][Full Text] [Related]
3. Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in loco-regionally advanced head and neck squamous cell carcinomas.
Vivek RS; Baludavid M; Mohanram R; ; ; ; ; ;
J Cancer Res Ther; 2006; 2(3):90-6. PubMed ID: 17998685
[TBL] [Abstract][Full Text] [Related]
4. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer.
Allal AS; Zwahlen D; Becker M; Dulguerov P; Mach N
Cancer J; 2006; 12(1):63-8. PubMed ID: 16613664
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study.
Pergolizzi S; Santacaterina A; Adamo B; Franchina T; Denaro N; Ferraro P; Ricciardi GR; Settineri N; Adamo V
Radiat Oncol; 2011 Nov; 6():162. PubMed ID: 22108341
[TBL] [Abstract][Full Text] [Related]
8. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
9. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
10. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
[TBL] [Abstract][Full Text] [Related]
11. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
[TBL] [Abstract][Full Text] [Related]
12. [Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
Qian W; Zhu G; Ji Q; Guo Y; Wang Y; Wang Y
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):217-22. PubMed ID: 24785284
[TBL] [Abstract][Full Text] [Related]
13. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice?
Agarwal JP; Gupta T; Kalyani N; Budrukkar A; Laskar SG; Murthy V; Kumar P; Narohna V; Pai P; Chaturvedi P; D'cruz AK
Indian J Cancer; 2011; 48(2):148-53. PubMed ID: 21768657
[TBL] [Abstract][Full Text] [Related]
17. Phase II study: concurrent chemo-radiotherapy in advanced nasopharyngeal carcinoma.
Maoleekoonpairoj S; Phromratanapongse P; Puttanuparp S
J Med Assoc Thai; 1997 Dec; 80(12):778-84. PubMed ID: 9470331
[TBL] [Abstract][Full Text] [Related]
18. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer.
Wanebo HJ; Glicksman AS; Landman C; Slotman G; Doolittle C; Clark J; Koness RJ
Am J Surg; 1995 Nov; 170(5):512-6. PubMed ID: 7485745
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL
World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091
[TBL] [Abstract][Full Text] [Related]
20. Weekly versus Three-Weekly Cisplatin-based Concurrent Chemoradiotherapy as definitive treatment in Head and Neck Cancer- Where do we stand?
Rawat S; Srivastava H; Ahlawat P; Pal M; Gupta G; Chauhan D; Tandon S; Khurana R
Gulf J Oncolog; 2016 May; 1(21):6-11. PubMed ID: 27250881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
